ALA also improved serum insulin levels in patients with NAFLD by reducing insulin resistance in two recent double-blind, placebo-controlled, randomized clinical trials [53, 54], and increased serum H2S levels, leading to improved glycemic status in T2DM patients [48]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.